Benzinga | Oct 13, 2020 08:32AM EDT

Morgan Stanley Maintains Overweight on Blueprint Medicines, Raises Price Target to $100

Morgan Stanley maintains Blueprint Medicines (NASDAQ:BPMC) with a Overweight and raises the price target from $92 to $100.